Table 1 Distribution of polymorphisms in healthy population and thyroid cancer patients (n = 50).

MTHFR C667T

CC

372(72.8%)

30(61.2%)

CT

126(24.7%)

18(46.15%)

0.09

1.77

0.96–3.29

TT

13(2.5%)

1(2.6%)

1

0.95

0.12–7.54

CT+TT

139(27.2%)

19(48.7%)

0.10

1.70

0.92–3.11

CYP1A1 T3801T

TT

327(64.2%)

27(57.4%)

TC

157(30.9%)

15(31.9%)

0.73

1.16

0.60–2.24

CC

25(4.9%)

5(10.6%)

0.09

2.42

0.86–6.83

CC+TC

182(35.8%)

20(42.5%)

0.35

1..33

0.73–2.44

CYP1A1 C4887A

CC

331(64.8%)

7(16.7%)

CA

162(31.7%)

30(71.4%)

< 0.0001

8.76

3.77–20.36

AA

18(3.5%)

5(11.9%)

< 0.0001

13.14

3.79–45.47

CA+AA

180(35.2%)

35(83.3%)

< 0.0001

9.19

4.00–21.12

GSTP1 A1578G

AA

170(33.5%)

18(38.3%)

AG

271(53.5%)

25(53.2%)

0.74

0.87

0.46–1.65

GG

66(13%)

4(8.5%)

0.45

0.57

0.19–1.75

AG+GG

337(66.5%)

29(61.7%)

0.52

0.81

0.44–1.51

GSTP1 C2293T

CC

389(76.3%)

30(75%)

CT

113(22.2%)

8(20%)

1

0.92

0.41–2.06

TT

8(1.5%)

2(5%)

0.17

3.24

0.66–15.95

CT+TT

121(23.7%)

10(25%)

0.85

1.07

0.51–2.26

GSTM1

P

233(45.4%)

24(48%)

D

280(54.6%)

26(52%)

0.77

0.90

0.50–1.61

GSTT1

P

385(75%)

16(32.7%)

D

128(25%)

33(67.3%)

< 0.0001

6.24

3.31–11.64

NAT2 G590A

GG

284(55.4%)

19(46.3%)

GA

181(35.3%)

17(41.5%)

0.34

1.40

0.71–2.77

AA

47(9.2%)

5(12.2%)

0.37

1.59

0.57–4.47

GA+AA

228(44.5%)

22(53.7%)

3.29

1.44

0.76–2.73

NQO*1 C609T

CC

295(58.5%)

30(61.2%)

CT

177(35.1%)

18(36.7%)

1

1

0.54–1.85

TT

32(6.4%)

1(2.04%)

0.34

0.31

0.04–2.33

CT+TT

209(41.5%)

19(38.74%)

0.76

0.89

0.49–1.63